Beth reiterated that most of her psychiatrists were talking about these side effects, and many were begin-ning to change patients to a major competitor’s prod-ucts. In reponse, Bob suggested that she downplay concerns about obesity and diabetes with these doctors. He also encouraged her to make more calls on primary-ucts. Doctors and prison-based physicians because Billing’s market research showed that they were less aware of Depolara’s side effects. He even gave her sales brochures to use that promoted Depolara as a “safe,gentle psychotropic suitable for people with mild men-tal illness.” “After all,” Bob said, “Billings Pharmaceuti-cals is counting on us to make our numbers.” However,Beth knew that “making the numbere” was increasingly difficult to do; doctors were becoming more aware of the side effects, and the issue was becoming more public.